NKGen Biotech
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NKGen Biotech sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
NKGen Biotech: 5 sponsored US clinical trials, 2 recruiting.
NKGen Biotech sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Moderate Alzheimer Disease, with 1 trials.
Upper-quartile sponsor footprint
NKGen Biotech sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Open-Label Extension Protocol to SNK01-AD01 Study
NCT07228078
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
NCT06189963
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
NCT05990920
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
NCT05099549
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
NCT03941262
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the NKGen Biotech pipeline
2 recruiting of 5 indexed (40% open); 2 completed (40%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Moderate Alzheimer Disease (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NKGen Biotech: open-pipeline peers nationwide
Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
NKGen Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this NKGen Biotech page
5 registered trials is a research-attention snapshot, not an endorsement of NKGen Biotech or any single study.
- 2 of NKGen Biotech's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Moderate Alzheimer Disease is the condition NKGen Biotech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Moderate Alzheimer Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NKGen Biotech pipeline card: 5 registered trials from official public datasets.Report a data error.